Form 4: Century Therapeutics COO Sells Shares for Tax Obligations Following RSU Vesting

Century Therapeutics' Chief Operations Officer, Adrienne Farid, sold 552 shares of common stock on June 9, 2025, at $0.622 per share, a non-discretionary transaction to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Adrienne Farid, Chief Operations Officer of Century Therapeutics, Inc. (IPSC), reported a sale of common stock.
• The transaction occurred on June 9, 2025.
• A total of 552 shares of common stock were disposed of at a price of $0.622 per share.
• Following this transaction, Adrienne Farid beneficially owns 250,141 shares of common stock.
• The sale was explicitly stated as being for the purpose of covering tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The filing clarifies that the sale was automatic and not at the discretion of the Reporting Person.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale to cover tax obligations, which is a common practice for equity compensation and does not indicate a change in management's view of the company's prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."

Industry Context

This filing is a routine insider transaction report (Form 4) detailing a non-discretionary sale of shares by a corporate officer to cover tax obligations related to RSU vesting. Such transactions are common across all industries when equity compensation vests and do not typically reflect broader industry trends or company-specific performance beyond the compensation structure.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in investment sentiment by the insider.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Adrienne Farid, Chief Operations Officer